Company intelligence / Profile preview
IRBM
Pomezia, Lazio, Italyirbm.com ↗
- Ownership
- Private
- Employees
- ~250
- Development stage
- Commercial
01
Overview
IRBM has a strong track record of delivering preclinical candidates that have progressed into clinical testing, with more than four drugs currently marketed that they contributed to discovering. They recently disclosed novel preclinical agents showing strong antitumor efficacy against aggressive brain tumors and acute lymphoblastic leukemia at AACR meetings in early 2024.
- Therapeutic areas
- OncologyNeurologyInfectious Diseases
- Modalities
- Small moleculesPeptidesAntibodiesExperimental adenoviral vaccines
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Collaborations with pharmaceutical companiesbiotech firmspartnerships span pharma, biotech, non-profit foundations
Beyond the preview
Go deeper on IRBM.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IRBM.